VC
OCRX

Vivo Capital’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Vivo Capital’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-153,331
Closed -$322K – 25
2016
Q4 		$322K Hold
153,331
– – 0.11% 23
2016
Q3 		$405K Hold
153,331
– – 0.13% 19
2016
Q2 		$291K Hold
153,331
– – 0.08% 20
2016
Q1 		$451K Buy
+153,331
New +$437K 0.11% 21

Other funds holding OCRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vivo Capital's OCRX Position: Q1 2017 in Review

Vivo Capital sold out of Ocera Therapeutics, Inc. (OCRX) in Q1 2017, closing a stake of 153,331 shares — an estimated $322K sold.

Vivo Capital first reported a position in OCRX in Q1 2016 and held it in 4 quarters. The position peaked at $451K in Q1 2016. 26 funds tracked by Wall St. Rank hold OCRX as of Q1 2017.

  • Vivo Capital reported no remaining Ocera Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Vivo Capital sold 153,331 Ocera Therapeutics, Inc. shares in Q1 2017, an estimated $322K.
  • Vivo Capital first reported a position in Ocera Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
  • Vivo Capital's Ocera Therapeutics, Inc. position peaked at $451K in Q1 2016.
  • 26 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q1 2017.

Based on Vivo Capital's 13F filing for Q1 2017, filed 15 May 2017.